SCHEMBL2065620

SCHEMBL2065620

CCSc1ccc2nc(C)cn2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.46
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
ALOX15 P16050 2/20 0.43
HSD17B10 Q99714 2/20 0.43
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
RXFP1 Q9HBX9 3/20 0.42
LMNA P02545 3/20 0.40
MAPT P10636 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
COMT P21964 1/20 0.40
PDE10A Q9Y233 4/20 0.38
POLB P06746 1/20 0.38
TP53 P04637 4/20 0.37
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25210945 0.76 KDM4E (0.52) KDM4EALDH1A1TSHRTDP1NPC1
SCHEMBL16885122 0.75 DYRK1A (0.49) DYRK1AKDM4EHPGDNPC1RAB9A
SCHEMBL2066703 0.75 DYRK1A (0.44) DYRK1AKDM4EALDH1A1HPGDALOX15
SCHEMBL3921056 0.74 DYRK1A (0.58) DYRK1AKDM4EALDH1A1HPGDHSD17B10
SCHEMBL3151360 0.74 DYRK1A (0.50) DYRK1AKDM4EALDH1A1HPGDHSD17B10
SCHEMBL2068243 0.71 PDE10A (0.53) DYRK1AKDM4EHSD17B10MAPTCOMT
SCHEMBL477109 0.69 DYRK1A (0.53) DYRK1AKDM4EALDH1A1HPGDHSD17B10
SCHEMBL17232819 0.69 DYRK1A (0.53) DYRK1AKDM4EALDH1A1HPGDHSD17B10
SCHEMBL29020764 0.69 DYRK1A (0.53) DYRK1AKDM4EALDH1A1HPGDHSD17B10
SCHEMBL1054695 0.69 DYRK1A (0.53) DYRK1AKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148524-B2 Process for producing sulfonyl chloride compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-04-03 US disclosed
EP-1932846-B1 METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND SUMITOMO CHEMICAL CO (JP) 2010-10-27 EP disclosed
US-20090247748-A1 PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-10-01 US disclosed
EP-1932846-A1 METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247748-A1 PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND SALL4, CLCN2, CLIC1 DYRK1A 1927/4885KDM4E 3606/4885ALDH1A1 1418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.